Endoscopic Ultrasound-Guided Gastroenterostomy Nationwide: Prospective Registry.

Launched by HOSPITAL UNIVERSITARI DE BELLVITGE · Nov 9, 2021

Keywords

ClinConnect Summary

This clinical trial is focused on a specific procedure called Endoscopic Ultrasound-Guided Gastroenterostomy (EUS-GE), which helps create a connection between the stomach and intestines. The goal is to safely introduce this technique in healthcare centers in Catalonia, while also providing training for medical professionals. By doing this, the researchers aim to reduce problems during the procedure and ensure that doctors are well-prepared to handle any challenges that may arise.

To be eligible for this trial, participants must be at least 18 years old and have a specific type of blockage in their stomach that can be due to either cancer or non-cancer conditions. They need to be able to understand the study and agree to participate by signing an informed consent form. Throughout the study, participants can expect to receive training and support related to the procedure, and they will undergo follow-up tests to monitor their progress. Overall, this trial aims to improve the safety of the EUS-GE technique and enhance the skills of the medical professionals performing it.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years or more
• • Gastric outlet obstruction (GOO) caused by passable /unpassable stenosis in the antrum-duodenal region, to malignant or non-malignant conditions
• • Patient capable of understanding and signing informed consent form
• • Patient understanding the type of study and complying with the follow-up of complementary tests during the study's duration
• Exclusion Criteria:
• • Massive ascites.
• • Complete stenosis
• • Failure to sign informed consent form
• • Patients with intellectual handicap who are unable to understand the nature and possible consequences of the study, unless there is a competent legal representative
• • Patients unable to adhere to subsequent follow-up requirements
• • Severe coagulation disorder: INR \> 1.5 not correctible with administration of plasma and/or platelets \< 50,000/mm3